Key result
Implanted cardioverter-defibrillator therapy was not associated with reduced mortality in patients with LVEF between 30% and 35%.
Why the study?
Trial evidence for ICD efficacy specifically for patients with LVEF near 35% is weak, as past trials were underpowered for this group and future trials are unlikely.
Cohort (n=6,109)
No
Answers are grounded in this paper and cite their sources.
BACKGROUND: Consensus guidelines support the use of implanted cardioverter-defibrillators (ICD) for primary prevention of sudden cardiac death in patients with either non-ischaemic or ischaemic cardiomyopathy with left ventricular ejection fraction (LVEF) ≤35%. However, evidence from trials for efficacy specifically for patients with LVEF near 35% is weak. Past trials are underpowered for this population and future trials are unlikely to be performed. METHODS: Patients with lowest LVEF between 30% and 35% without an ICD prior to the lowest-LVEF echo (defined as 'time zero') were identified by querying echocardiography data from 28 November 2001 to 9 July 2020 at the Massachusetts General Hospital linked to ICD treatment status. To assess the association between ICD and mortality, propensity score matching followed by Cox proportional hazards models considering treatment status as a time-dependent covariate was used. A secondary analysis was performed for LVEF 36%-40%. RESULTS: Initially, 526 440 echocardiograms representing 266 601 unique patients were identified. After inclusion and exclusion criteria were applied, 6109 patients remained for the analytical cohort. In bivariate unadjusted comparisons, patients who received ICDs were substantially more often male (79.8% vs 65.4%, p<0.0001), more often white (87.5% vs 83.7%, p<0.046) and more often had a history of ventricular tachycardia (74.5% vs 19.1%, p<0.0001) and myocardial infarction (56.1% vs 38.2%, p<0.0001). In the propensity matched sample, after accounting for time-dependence, there was no association between ICD and mortality (HR 0.93, 95% CI 0.75 to 1.15, p=0.482). CONCLUSIONS: ICD therapy was not associated with reduced mortality near the conventional LVEF threshold of 35%. Although this treatment design cannot definitively demonstrate lack of efficacy, our results are concordant with available prior trial data. A definitive, well-powered trial is needed to answer the important clinical question of primary prevention ICD efficacy between LVEF 30% and 35%.
No takes yet. Share an insight, caveat, or question.
Wasfy et al. (2023) conducted a cohort in Left ventricular ejection fraction between 30% and 35% (n=6,109). Implanted cardioverter-defibrillators (ICD) vs. No ICD was evaluated on Mortality (HR 0.93, 95% CI 0.75-1.15, p=0.482). Implanted cardioverter-defibrillator therapy was not associated with reduced mortality in patients with LVEF between 30% and 35%.
Synapse has enriched 10 related papers. Consider them for comparative context: